Smallpox vaccine (NYCBH vaccinia strain) - sanofi pasteur/NIAID

Drug Profile

Smallpox vaccine (NYCBH vaccinia strain) - sanofi pasteur/NIAID

Alternative Names: Aventis Pasteur smallpox vaccine (APSV); NYCBH vaccinia strain smallpox vaccine - Aventis Pasteur; Vaccinia virus vaccine - NIAID/Aventis Pasteur; Wetvax

Latest Information Update: 16 Mar 2009

Price : $50

At a glance

  • Originator sanofi pasteur
  • Developer National Institute of Allergy and Infectious Diseases; sanofi pasteur
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Smallpox

Most Recent Events

  • 21 Jan 2005 Aventis Pasteur is now called sanofi pasteur.
  • 13 Oct 2004 A clinical study has been added to the adverse events and Viral Infections immunogenicity sections ,
  • 03 Jul 2003 A case report has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top